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Abstract
Intensive care unit‑acquired weakness (ICU‑AW) is an increasingly complication of survivors of 
critical illness. It should be suspected in the presence of a patient with a flaccid tetraparesis or tetra‑
plegia with hyporeflexia or absent deep tendon reflexes and difficult to weaning from mechanical 
ventilation in the absence of different diagnoses. Important risk factors are age, sepsis, illness du‑
ration and severity, some drugs (neuromuscular blockers, steroids). Electrophysiological studies 
have shown an axonal damage of involved peripheral nerves (critical illness polyneuropathy). Ho‑
wever, muscle can also be primitively affected (critical illness myopathy) leading to ICU‑AW with 
inconstant myopathic damage patterns in electromyographic studies. Mixed forms can are present 
(critical illness polyneuromyopathy. Although the pathophysiology remains obscure, the hypothesis 
of an acquired channelopathy is substantial. Electroneuromyography is crucial for diagnosis. Mu‑
scular and nerve biopsies are necessary for diagnosis confirmation. Aggressive treatment of baseline 
disease, prevention, through avoiding or minimizing precipitating factors, strict glycemic control, 
and early rehabilitation combining mobilization with physiotherapy and muscle electrical muscle 
stimulation, are the keys to improving recovery of the affected individuals. This narrative review 
highlights the current literature regarding the etiology and diagnosis of ICU‑AW. 
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Introduction
Sir W. Osler did the first description of weakness in critical illness patients in the pre‑antibiotic era [1], 
when he described a rapid loss of flesh in a person with prolonged sepsis and multiorgan failure. At 
the end of ‘70s and first ‘80s, physicians and neurologists pointed their attention in some patients that 
developed weakness of the limbs, arms or both with absent or hypoactive deep tendon reflexes, atrophy 
or loss of muscle fibers, fasciculations and frequently tetraparesis or tetraplegia after recovery from 
severe sepsis or other devastating inflammatory states [2‑8]. These observations were more frequent as 
survival rates among patients in the intensive care unit (ICU) increased, and ICU‑acquired weakness 
(ICU‑AW) increased relevance for care providers outside the ICUs. Since then, numerous case series 
and observational studies of ICU‑AW have led to an explosion in the number of terms used to describe 
this syndrome (critical illness polyneuropathy (CIP), critical illness myopathy (CIM), CRIMYNE, etc.)
[9‑11]. As a result, only recently a new scheme to diagnose and classify ICU‑AW has been proposed 
to ensure consistent identification of ICU‑AW patients [12]. Motor weakness may be related to (1) 
pre‑existing neuromuscular disorder leading to ICU admission, (2) new‑onset or previously undiagno‑
sed neurological disorder, or (3) complications of non‑neuromuscular critical illness. Neuromuscu‑
lar syndromes related to ICU treatment consist of CIP, CIM, and prolonged neuromuscular blockade 
(PNB). They are recognized as a frequent cause of newly acquired weakness in ICU patients. Using this 
diagnostic definition, ICU‑AW can be recognized more quickly permitting more uniform reporting of 
affected patients by intensivists.
By definition, ICU‑AW is a tetraparesis or tetraplegia with hyporeflexia, or absent deep tendon re‑
flexes muscle wasting, and difficulty weaning from the ventilator. Evaluation of these patients is based 
on neurological examination, detailed electrophysiological investigation, serum creatine kinase (CK) 
level, knowledge of clinical setting and predisposing factors, other laboratory studies as needed, and 
histological examination of muscle biopsy. Without electrophysiological studies, it is impossible to 
define and to characterize ICU‑AW, phrenic nerve conduction, diaphragm electromyography, blink 
reflex, and the technique of direct muscle stimulation (DMS) could be employed together with conven‑
tional nerve conduction studies and needle electromyography. Today, ICU‑AW should be suspected in 
any patient who develops generalized muscle weakness or impossibility to wean from the mechanical 
ventilator after recovering from a severe critical illness [4‑8]. Primary differential diagnoses of critical 
illness related paralysis are incidental Guillain‑Barré syndrome (GBS) and unmasked myasthenia gra‑
vis. Less frequent diagnosis to consider are atypical presentation of amyotrophic lateral sclerosis (ALS), 
polymyositis or other myopathies, and precipitation of porphyria or rhabdomyolysis due to drugs used 
in the ICU. Recently a poliomyelitis‑like flaccid paralysis due to West Nile virus infection was reported 
[13]. A subgroup of patients with myasthenia gravis with muscle‑specific tyrosine kinase antibody is 
noted to present as respiratory crisis [14]. Although no specific treatment exists for ICU‑AW, under‑
standing its etiology, pathophysiology, and risk factors may be significant for the prevention. Because 
the diagnosis and the management of ICU‑AW can be sometimes difficult, this narrative review aims to 
help in organizing a practical approach to the diagnosis and management of ICU‑AW patients.
Incidence
The real incidence of ICU‑AW is unclear and varies between studies. This variability reflects different 
populations, risk factors, definitions of this syndrome, absence of diagnostic criteria widely validated 
and the difficulty to differentiate all clinical forms adequately [6‑9]. It ranges between 7% in patients 
undergoing liver transplantation [15] to 33% in patients admitted to the intensive care unit with status 
asthmaticus [16]. Recent reviews report an incidence of 30 to 46%, mainly, secondary to sepsis and 
multi‑organ dysfunction syndrome (MODS) [10,17]. The incidence is also higher (30‑60%) in patients 
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with acute respiratory distress syndrome (ARDS), especially in patients with long‑term (> 1 week) du‑
ration of mechanical ventilation [7,18,19]. Seventy percent of patients with sepsis may suffer from CIP 
[6]. In children, the risk is less well defined as there are no prospective clinical and electrophysiologic 
studies.
Short‑ and long‑term outcomes
ICU‑AW appears to influence short and long‑term measures of outcome. However, the risk of selection 
bias in published studies is high due to the combination of varied definitions of neuromuscular impai‑
rment and the use of selected cohorts. When the combination of severe sepsis, septic shock, and coma 
are present, mortality is near to 100% [7,8,20,21]. However, there is not yet a definite cause‑and‑effect 
relationship. No conclusive evidence exists to refute the possibility that poor outcomes and weakness 
may only reflect the type and severity of the patient’s underlying pathology [22]. Furthermore, muscle 
wasting and weakness are common among ICU‑AW survivors in long‑term follow‑up studies [23]. 
Latronico and colleagues evaluated 36 studies (n=263 patients) reporting long‑term outcomes in hete‑
rogeneous ICU‑AW populations [24], indicating a complete functional recovery (defined as breathing 
spontaneously and walking independently) in 68% of cases. A severe disability (defined as quadripa‑
resis, quadriplegia, or paraplegia) was present in 28% of cases. Persisting milder disabilities (reduced 
or absent deep tendon reflexes, stocking and glove sensory loss, muscle atrophy, painful hyperesthesia, 
and foot drop) are common even in patients with complete functional recovery [25].
Risk factors
Table I summarizes the known clinical risk factors of ICU‑AW. Multiple risk factors have been identi‑
fied.
Risk factors References
Advancing age Bercker et al. [18], De Letter et al. [20] 
Female gender De Jonghe et al. [26]
Increased severity of illness de Letter et al. [20], De Jonghe et al. [26], Bednarik et al. [27]
Systemic inflammatory response syndrome Jaber et al. [28], Levine et al. [29]
Multiorgan system failure De Jonghe et al. [26]
Sepsis Garnacho‑Montero et al. [30]
Hyperglycemia Van den Berghe et al. [31]
Medications Latronico et al. [8], Bercker et al. [18], de Letter et al. [20], De Jonghe et 
al. [26], Bednarik et al. [27], Garnacho‑Montero et al. [30]
Corticosteriods De Jonghe et al. [26]
Neuromuscular blocking agents MacFarlane and Rosenthal [31], Leatherman et al. [32]
Aminoglycosides Latronico et al. [8], Bercker et al. [18] de Letter et al. [20], De Jonghe et al. 
[26], Garnacho‑Montero et al. [30]
Parenteral nutrition Waldhausen et al. [33], Marino et al. [34]
Long duration of mechanical ventilation De Jonghe et al. [26]
Catabolic state Garnacho‑Montero et al. [30], Trojaborg et al. [35]
Immobility Levine et al. [36]
Combination of any of the above factors Hund et al. [37]
Table I. Intensive Care Unit Acquired Weakness (ICU‑AW) risk factors
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Undoubtedly, important risk factors are age, sepsis, the duration and the severity of illness, as measured 
by ICU admission Acute Physiology and Chronic Health Evaluation score or Sequential Organ Failure 
Assessment score, systemic inflammatory response syndrome (SIRS), and MODS [18‑22]. The use of 
neuromuscular blocking agents, vasopressors, corticosteroids, aminoglycosides and opioids, princi‑
pally fentanyl, were also associated to ICU‑AW. Only anecdotal reports link ICU‑AW and administra‑
tion of parenteral nutrition with the speculation that the use of intravenous fat emulsions with high 
amounts of polyunsaturated fatty acids could cause axonopathy [33,34]. Furthermore, additional risk 
factors include neurological compromise, hyperglycemia, hypoalbuminemia, hyperosmolarity, paren‑
teral nutrition, renal failure with or without replacement therapy, female sex, joint contractures, and 
muscle wasting from catabolism and physical inactivity also contribute to ICU‑AW [8,10,17,38,39]. 
Short‑term immobility impairs microvascular function and induces insulin resistance [40], increases 
production of pro‑inflammatory cytokines and reactive oxygen species, resulting in muscle proteolysis 
and a net loss of muscle protein and subsequent muscle weakness [41]. Prolonged immobility leads to 
decreased muscle protein synthesis, increased muscle catabolism, and decreased muscle mass, espe‑
cially in the lower extremities. However, the presence of so many risk factors suggests that several 
factors act synergistically in the development of ICU‑AW.
Clinical Picture: evaluation and diagnostic 
criteria for ICU‑AW
The classical clinical findings are flaccid tetraparesis, frequently symmetrical with hypo or areflexia 
(major finding); atrophy and loss of muscle mass (minor finding) [4‑8,25]. An initial examination 
should be performed upon admission to the ICU, with subsequent examinations paired with daily 
awakenings or when patients show signs of clinical improvement, allowing cooperation with a more 
comprehensive examination. The diagnosis of ICU‑AW should begin with routine physical and neu‑
rological examination of a patient that is weak following an episode of critical illness with the use of 
the Medical Research Council (MRC) scale. The MRC score is a tool that help to graduate the muscle 
strength of various muscle groups in the upper and lower extremities [36]. It ranges from 0 to 5, with 
higher scores indicating greater muscle strength [36]. It has maximal punctuation of 60. A combined 
score of 48 points is a cut‑off for presumptive diagnosis of ICU‑AW [26]. Patients with ICU‑AW accor‑
ding to the MRC score should undergo serial evaluations, and if persistent deficits are noted, electro‑
physiological studies, muscle biopsy, or both are warranted. Unfortunately, the MRC scale has several 
limitations due to discrimination and a potential ceiling effect, and we need better bedside tools for 
identifying the presence of ICU‑AW.
Furthermore, weakness can also have a broad differential diagnosis. Table II summarizes common di‑
seases that cause weakness in ICU patients.
Onset of ICU‑AW may not be easily appreciated. It is often brought to the attention because of flac‑
cidity and wasting of extremities or difficulty in weaning the patient from mechanical ventilation. 
Standard neurological examination should be adapted to patient clinical condition because patients’ 
cooperation is often difficult to obtain, muscle strength testing may be inadequate and sensory exa‑
mination not reliable. Acute motor deficits due to central nervous system (CNS), upper motor neu‑
ron injury may cause hypotonia and hyporeflexia similar to lower motorneuron lesions, and clinical 
differentiation between central and peripheral causes becomes difficult. Neuromuscular and CNS 
involvement may also be coincidental. Three major features usually point toward CNS involvement: 
asymmetric neurologic signs (hemispheric lesion), altered mental status (diffuse encephalopathy), 
and cranial nerve palsies (brain stem lesion). Appropriate imaging (computed tomography, magne‑
tic resonance imaging) and electroencephalogram usually provide the diagnosis. Many spinal cord 
Localization Pre‑existing Previously undiagnosed/new‑onset Critical illness related
Spinal cord Trauma Acute ischemia Not described
Infarction Epidural abscess
Transverse myelitis Acute transverse myelitis
Anterior horn cell Amyotrophic lateral sclerosis Amyotrophic lateral sclerosis 
(predominant diaphragm weakness)
Hopkins syndrome
Poliomyelitis 
(West Nile virus)
West Nile virus poliomyelitis
Peripheral nerve Guillain‑Barre´ syndrome Incidental Guillain‑Barre´ syndrome Critical illness 
polyneuropathy
Chronic inflammatory 
demyelinating 
polyneuropathy
Porphyria, vasculitis, toxic, compressive
Neuromuscular 
junction
Myasthenia gravis Unmasked myasthenia gravis Prolonged neuromuscular 
blockade
Lambert‑Eaton syndrome Atypical myasthenia gravis (predominant 
respiratory weakness, muscle‑specific 
tyrosine kinase antibody)
Botulism Toxic
Muscle Muscular dystrophy Rhabdomyolysis Critical illness myopathy
Polymyositis Toxic myopathies
Periodic paralysis Polymyositis
Metabolic/congenital Myotonic dystrophy
Mitochondrial Adult‑onset acid maltase deficiency 
Pyomyositis Hypokalemic 
Hypophosphatemic
Table II. Diseases and syndromes causing weakness in patients in the ICU: differential diagnosis
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lesions, such as acute transverse myelitis, epidural abscess, and spinal cord infarct, may present as 
causes of ICU‑AW. In the presence of flaccid weakness due to spinal shock, upper versus lower motor 
neuron paralysis cannot be distinguished. Presence of sensory level on trunk (when it is possible 
to investigate), Babinski sign, flexor spasms, loss of anal reflex, loss of sphincter control, and arms 
weaker than legs are some useful signs of spinal cord involvement. Magnetic resonance imaging of 
the spine is the most useful procedure in any suspicion of a spinal cord lesion. The main clinical 
features of neuromuscular diseases are weakness and wasting of extremities, hypotonia, and hypo‑
reflexia/areflexia, with or without respiratory and/or cranial musculature involvement. The diseases 
of the anterior horn cell, neuromuscular junction, and muscle produce pure motor syndromes. Most 
peripheral nerve disorders have sensory and motor findings. Clinical distinction among these cate‑
gories may be difficult in the ICU setting because of the impossibility in eliciting signs, overlapping 
features and simultaneous occurrence of more than one syndrome. Some helpful clinical signs are 
asymmetric weakness and fasciculations (ALS, viral poliomyelitis); paresthesia, sensory deficits, and 
distal symmetric weakness (peripheral neuropathy); cranial nerve palsies and dysautonomia (GBS); 
and combination of ptosis and weakness of eye closure (myasthenia gravis, prolonged neuromu‑
scular junction blockade). Given the complexities of ICU‑AW, a standard and practical definition is 
evidently difficult. To date the nosologic scheme by Stevens et al. [10,12] is a reasonable classification. 
ICU‑AW should be applied in cases in which a patient is noted to have clinically detected weakness 
Undoubtedly, important risk factors are age, sepsis, the duration and the severity of illness, as measured 
by ICU admission Acute Physiology and Chronic Health Evaluation score or Sequential Organ Failure 
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with no plausible cause other than critical illness. ICU‑AW, with documented polyneuropathy, myo‑
pathy, or both, can be subclassified.
CIP refers to ICU‑AW with electrophysiological evidence of an axonal polyneuropathy. CIM refers to 
ICU‑acquired weakness with myopathy that is documented electrophysiologically or histologically. 
CINM refers to electrophysiological or histologic findings of both CIP and CIM [10,12]. Knowledge of 
clinical background in which the weakness evolves is an essential guide to differential diagnosis. CIP 
often follows sepsis [30], SIRS [28,29] and MODS [26]. CIM often occurs in the setting of treatment 
with intravenous corticosteroids [26] and non‑depolarizing neuromuscular blocking agents [31,32], 
such as in patients with asthma, pneumonia, organ transplant, and renal failure [7,16,24,31,37]. The 
contribution of electrophysiological studies has been invaluable in identifying the different clinical 
forms [4‑6,8,11,24,42]. However, there are some difficulties to define electromyography and nerve con‑
duction studies as accurate [4‑6,8,11,24]. They are difficult to perform in many critically ill patients. 
The patients must be awake and able to collaborate; patients in the ICU are often not able to contract 
their muscles voluntarily. Tissue edema can confound nerve conduction studies. Further investigation 
with biochemical studies and muscle biopsy are often necessary to arrive at a definitive diagnosis. Ele‑
vation of creatine kinase (CK) levels is associated with muscle necrosis but is not of diagnostic use on 
its own due to low sensitivity. Muscle biopsy in ICU paralysis syndromes may be helpful in arriving at 
an accurate diagnosis or to classify the type of CIM. Nerve biopsy is only rarely indicated. Clinical, 
electrophysiological, and histological features of ICU‑AW are summarized in Table III.
CIP GBS
Prodromal conditions Sepsis and multiple organ failure Gastrointestinal or respiratory infection
Clinical presentation Onset of the disorder usually after intensive care 
unit admission
Onset of the disorder usually before intensive 
care unit admission
Often characterized by fairly symmetric limb 
muscle weakness sparing cranial nerves;
Infections precede the onset of progressive 
weakness and sensory disturbances
Sensory deficits less prominent Frequent cranial nerve involvement
Cerebrospinal fluid Usually normal Albumin‑cytologic dissociation
Electrophysiology Axonal motor and sensory polyneuropathy Demyelinating polyneuropathy or unresponsive 
nerves, abundant spontaneous activity
Axonal motor and sensory polyneuropathy
Nerve ultrasound Elevated mean muscle echotexture and 
fasciculations in more arm and leg muscle 
groups with lower punctuations at the 
ultrasound pattern scores (UPS) at the 
examination of peripheral sensorimotor nerves 
(A), roots and vagus (B), and sural nerve (C)
Sonographic evidence of higher cross‑sectional 
area values (CSA) of the ulnar, radial, tibial nerve 
and brachial plexus with higher punctuations at 
the ultrasound pattern scores at the examination 
of peripheral sensorimotor nerves (A), roots and 
vagus (B), and sural nerve (C)
Magnetic resonance 
imaging
No significant findings Occasional enhancement of spinal nerve roots
Biopsy Primarily axonal degeneration of distal 
peripheral nerves without inflammation
Primarily demyelinating process with 
inflammation, or motor/sensory axonal 
degeneration, or motor axonal degeneration only
Treatment No specific therapy, usually anti‑septic treatment Plasmapheresis, intravenous immune globulin
Outcome Recovery may be spontaneous and of variable 
timing; 50% of patients with full recovery
Usually > 75% complete recovery
Table III. Differentiation between critical illness polyneuropathy (CIP) and Guillain‑Barré syndrome (GBS)
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Electromyography and nerve 
conduction studies
Electromyography is an essential method of 
making a final or differential diagnosis. A re‑
duction in the amplitude of compound muscle 
action potentials (CMAP) or sensory nerve ac‑
tion potentials (SNAP), or both, with preserved 
conduction velocity and normal distal motor 
latencies, in addition to normal responses to re‑
petitive nerve stimulation, may be seen within 
2–5 days after the onset of symptoms. The re‑
duction in amplitude often precedes clinical 
presentation and accompanying fibrillation po‑
tentials and positive sharp waves that may oc‑
cur in the second or third week (Figure 1) [43].
The duration of CMAPs is an important indica‑
tor of CIM, and it accompanies the fall in am‑
plitude [43]. CMAP duration can be 2‑3 times 
longer compared to healthy controls and is 
most pronounced in lower limb nerves (Figu‑
re 2).
Electrophysiological screening is showing 
CMAP duration reductions below two standard 
deviations of the normal value accurately iden‑
Figure 1. Typical nerve conduction studies in presence of CIP registered on median and common 
peroneal nerve and derived from abductor brevis pollicis (ABP) and anterior tibialis (Tib Ant), 
respectively. In CIP, CMAP amplitude is reduced (corresponding to loss of axons), with normal 
conduction velocity in surviving axons
Figure 2. Typical nerve conduction study 
in presence of CIM registered on common 
peroneal nerve and derived from anterior 
tibialis (Tib Ant). In CIM, CMAP amplitude 
is reduced, together with an increase of 
CMAP duration with normal conduction 
velocity. Sarcolemmal inexcitability causes 
low amplitude CMAPs) that may have 
prolonged durations
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tifies patients with CIP or CIM, increased duration of CMAP will permit to identify patients with CIM 
[44,45]. Patients admitted for sepsis or SIRS showing electromyographic signs of characteristic CMAP 
potentials in early stages, and an abnormal baseline nerve conduction study are more likely to develop 
acquired neuromuscular dysfunction with increased hospital mortality [44].
Baum et al. [45] identified four different clusters of electrophysiological impairment in patients with 
sepsis/SIRS, which enabled further differentiation of the severity of neuromuscular disturbances in 
sepsis‑associated organ failure:
 • Cluster 1: normal values for CMAP, SNAP, and nerve conduction velocity in all nerves, which ac‑
counted for 10% of total patients;
 • Cluster 2: pathological values for CMAP in the lower extremities and other parameters normal, 
which accounted for 17% of patients;
 • Cluster 3: moderate pathological values for CMAP, SNAP, and sensory nerve conduction velocity 
in upper and lower extremities and motor nerve conduction velocity in lower extremities, which 
accounted for 40% of patients;
 • Cluster 4: severe disturbances of CMAP, SNAP, and nerve conduction velocity in upper and lower 
extremities, which accounted for 33% of patients.
Varying degrees of fibrillation potentials and positive sharp waves can be recorded in both CIP and 
CIM. Abnormal SNAPs are characteristic for CIP, although local edema may interfere with optimal 
sensory nerve stimulation and recording. CIM is characterized by significant slowing of the muscle fi‑
ber conduction velocity or even muscle fiber conduction block during the acute phase, which correlates 
with a prolonged CMAP duration and altered muscle fiber excitability [43]. The earliest electrophysio‑
logical sign of CIP is a reduction of CMAP amplitudes, with a minor change in latency. These changes 
are typical of axonal damage but are also associated with severe myopathy, including CIM. Fibrillation 
potentials and positive sharp waves may not appear in the muscle until 3 weeks after onset. Motor unit 
potentials (MUP), if they can be voluntarily activated by the patient, will often appear polyphasic and 
normal or somewhat low in amplitude, suggesting an associated primary involvement of muscle. These 
electrophysiologic changes, however, are not specific and are also produced by a primary myopathy. 
Despite electrodiagnostic technical difficulty in critically ill patients, it is important to demonstrate a 
reduction of SNAP amplitudes before a firm electrophysiologic diagnosis of polyneuropathy can be 
made; this finding is not present in many instances. There is some evidence that some patients with 
CIM demonstrate increased CMAP duration [46], but this finding needed further validation. In sup‑
port of that, in vitro single muscle fiber excitability studies have demonstrated a reduction in muscle 
fiber conduction velocity that is inversely proportional to the degree of muscle weakness in CIM [47]. 
The CMAP amplitude prolongation was also proportional to the degree of weakness and phase of ill‑
ness.
A simplified screening method of ICU‑AW is based on the daily measurement of peroneal CMAP am‑
plitude [48]. In a prospective multicenter study of 92 intensive care unit patients, a reduced CMAP am‑
plitude on peroneal nerve by more than 2 standard deviations predicts neuromuscular complications 
of critical illness within a 67% specificity [48]. All affected patients developed the electrophysiological 
change within 13 days of intensive care unit admission with a median time of 6 days. This change in 
CMAP amplitude was abrupt over 1 day in most cases but took place over several days in others.
Repetitive nerve stimulation studies to demonstrate a defect in neuromuscular transmission should 
also be performed in suspicious cases. This defect does not occur in sepsis but will be present if neuro‑
muscular blocking agents have been used. Their effects may persist beyond several hours for a number 
of days if the patient is in renal failure or liver failure [45]. Phrenic nerve conduction studies and, in 
some cases, needle electromyography of chest wall muscles and the diaphragm are safe and can esta‑
blish respiratory muscle involvement in patients who are difficult to wean from the ventilator [50]. 
Electrophysiological features of CIM include reduction of CMAP amplitudes (less than 80%) and 
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perhaps in some cases increased duration in 2 or more nerves with normal or near normal sensory 
nerve action potential amplitudes (more than 80%). There should be an absence of decrement on re‑
petitive nerve stimulation. Myopathic changes should be seen on needle examination, with or without 
fibrillation potentials [51].
Tzanis et al. [52] have proposed that maximum inspiratory pressure may serve as a surrogate indicator 
for the assessment of CIP and CIM. The authors measured maximum inspiratory pressure using the 
unidirectional valve method, independent of the patient’s ability to cooperate. A significant correlation 
was found between maximum inspiratory pressure and the MRC scale score (r = 0.68, P < 0.001) [52]. 
The findings indicated that maximum inspiratory pressure, estimated using the unidirectional valve 
method, may be useful for early detection of intensive care unit‑acquired weakness [52]. Electrophysio‑
logical findings should always be correlated with clinical findings. In difficult cases, muscle biopsy may 
be required for a definite diagnosis.
Direct muscle stimulation (DMS)
To overcome the challenges of patient cooperation and completely avoid muscle biopsy, the method of 
DMS has been evaluated. First proposed by Rich et al. in 1996 [53], DMS was intended to differentia‑
te between CIM and CIP. Both conditions demonstrate reduced nerve‑evoked CMAP amplitude. Yet 
denervated muscle (as in CIP) should retain electrical excitability and after DMS, CMAP amplitude 
should be normal. CIM patients should exhibit loss of electrical excitability and both nerve‑ and after 
DMS, CMAPs should be diminished. The ratio of nerve stimulated CMAP to muscle stimulated CMAP 
amplitude should be more than 0.5 in CIM (and in normal controls) and less than 0.5 in CIP. Troja‑
borg and colleagues [35] applied those techniques in addition to the motor unit number estimates and 
quantitative electromyography to classify 22 consecutive patients with critical illness related weakness 
as having primarily neurogenic or myopathic features. These authors found that electrophysiological 
abnormalities supported a myopathy in all cases.
Muscle and nerve ultrasounds
Muscle and nerve ultrasounds appear as a new tool that can help to establish and early diagnosis of this 
entity [54,55]. In CIM, a controlled and observational study in patients with sepsis showed muscular 
fasciculations more frequently and in greater numbers of regions affected principally in proximal and 
distal arms and legs, additionally, 75% of them had alterations in normal echotexture of examined mu‑
scles [55]. In the same manner, the use of ultrasound pattern sum score (UPSS) and its sub‑scores can 
help in identify CIP [54]. These methods until now are under investigation and cannot replace electro‑
neuromyography and nerve conduction studies or muscular biopsy although showing high sensitivity, 
specificity, and predictive positive values.
Muscle biopsy
Muscle biopsy is still considered the gold standard for confirming muscle involvement in the disease 
process despite its invasiveness. Critical illness myopathy is pathologically classified into five subtypes: 
(1) thick filament myopathy; (2) acute myopathy with scattered necrosis; (3) acute myopathy with dif‑
fuse necrosis; (4) disuse cachectic myopathy; and (5) rhabdomyolysis (Figure 3) [8,38].
Although unusual, myopathy can progress to frank rhabdomyolysis. CIP presents as morphological 
signs of axonal degeneration in both type 1 and type 2 fibers, resulting in extensive denervation atrophy 
of muscles. During recovery, muscle biopsy may show grouped atrophy of muscle fibers. Furthermore, 
angular atrophy of isolated scattered muscle fibers has been observed as part of an acute denervation 
process [8,38]. However, clinical characteristics and examination results should be carefully evaluated 
for the correct diagnosis of CIP and CIM [8,38].
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ICU‑AW clinical subtypes
Critical illness polyneuropathy (CIP)
CIP is a diffuse and symmetric sensorimotor axonal neuropathy [30]. In CIP we can observe a distal 
loss of sensitivity to pain, vibration, and temperature, and often the patients have difficult to breath 
spontaneously or to be weaned from mechanical ventilation due to phrenic nerve and diaphragm in‑
volvement [25,50]. The mechanism of axonal degeneration may be multifactorial, including: impaired 
oxygen and nutrient delivery from microcirculatory dysfunction in peripheral nerves, due to sepsis 
and/or hyperglycemia, and increased endoneuronal edema, due to cytokine‑induced changes in mi‑
crovascular permeability; and neuronal bioenergetics failure from mitochondrial dysfunction, due to 
increased uptake of glucose and subsequent reactive oxygen species generation [4,8,38]. Furthermore, 
cytokines may exert direct toxic effects on peripheral nerves, and there may be a humoral neurotoxic 
factor involved in the pathogenesis of CIP [4,8,38]. The morphologic features of CIP have been demon‑
strated through the biopsy of peripheral nerve and muscle [5]. There is a primary axonal degeneration 
of peripheral nerve motor and sensory fibers, but no evidence of inflammation, as may be seen in GBS. 
Muscle shows scattered atrophic fibers in acute denervation and grouped atrophy in chronic denerva‑
tion. Immunohistochemistry of muscle biopsy specimens demonstrates upregulation of HLA‑DR, the 
proinflammatory cytokine tumor necrosis factor‑R75, and the anti‑inflammatory cytokine IL‑10 when 
Figure 3. Muscle biopsy (vastus lateralis muscle) from a normal subject (A). ATPase/Toludine blue 
staining differentiates type I, IIa and IIb muscle fibres as indicated. (B) CIM. A predominant type II 
(fast twitch) muscle fibre atrophy. (C) Hematoxylin‑eosin staining in CIM. Atrophic fibers stained 
poorly, and in some fibers, a feathery degeneration of the cytoplasmic content was seen (arrows)
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compared to controls [56]. The only CNS manifestation is central chromatolysis of anterior horn cells 
and loss of dorsal root ganglion cells, secondary to the peripheral nerve axonal damage. No changes 
appear distinctive of CIP. A definite diagnosis of CIP requires that the following criteria be met: (1) The 
critically ill patient develops limb weakness or difficulty in weaning, after non‑neuromuscular causes 
such as heart and lung diseases have been excluded; (2) electromyography shows axonal motor and 
sensory polyneuropathy; (3) absent decremental response to repetitive nerve stimulation [57].
Critical illness myopathy (CIM)
CIM occurs more frequently than CIP, and it is associated with a higher rate of recovery [58]. CIM 
represents a spectrum of ICU‑acquired muscle pathology involving metabolic, inflammatory, and bio‑
energetics muscle derangements. CIM patients characteristically have early loss of muscle tissue (ca‑
chexy myopathy), but with conservation or slightly reduced deep tendon reflexes. In CIM, levels of CK 
are often high, and others blood exams can show evidence of SIRS, sepsis, and multiorgan compromise 
[7,24,38,59]. Frequently high levels of CK are observed [7,24,38,60]. Decreased oxygen and nutrient 
delivery to muscles, upregulation of protein catabolism by pro‑inflammatory cytokines, decreased ex‑
pression of myofibrillar repair genes, and an imbalance in anabolic and catabolic hormones contribute 
to CIM. The reported light‑microscopic findings in specimens from CIM patients include muscle fiber 
atrophy (preferentially type II fibers), occasional fiber necrosis, regeneration, and decreased or absent 
reactivity in myofibrillar adenosine triphosphatase staining, corresponding to a selective loss of myosin 
filaments. This selective loss of myosin is practically pathognomonic for CIM [51,61]. To minimize 
the morbidity of an open muscle biopsy, some have proposed quantification of myosin/actin ratio by 
gel electrophoresis in core needle specimens (conchotome muscle biopsy technique) to diagnose CIM 
[62]. A definite diagnosis of CIM requires that the following criteria be met: (1) The critically ill patient 
develops limb weakness or difficulty weaning, after non‑neuromuscular causes such as heart and lung 
diseases have been excluded; (2) compound muscle action potential amplitudes are less than 80% of 
the normal lower limit in two or more nerves without conduction block; (3) sensory nerve action po‑
tential amplitudes are greater than 80% of the normal lower limit; (4) needle electromyography shows 
short duration, low‑amplitude motor unit potentials with early or normal full recruitment, with or 
without fibrillation potentials, in conscious and collaborative patients, or increased compound muscle 
action potential duration or reduced muscle membrane excitability by direct muscle stimulation in 
non‑collaborative patients; (5) absent decremental response to repetitive nerve stimulation; (6) muscle 
histopathology shows primary myopathy [57].
Critical illness polyneuromyopathy (CINM)
CIP and CIM often coexist, commonly referred to collectively as CINM. Muscle that is functionally 
denervated (from CIP) and directly injured (from CIM) may have increased susceptibility to additional 
insults and injury (e.g., corticosteroid‑induced myopathy). Furthermore, weakness from CINM may 
be enhanced by immobility [25]. When sought, myopathy is often present in conjunction with the 
established evidence for neuropathy [8,25]. For example, Latronico et al. demonstrated that 19 of 24 
patients with CIP had evidence of myopathy when muscle biopsy was performed [25].
Prolonged neuromuscular blockade (PNB)
The condition may coexist with CIP or CIM and has been reported to progress to CIM on sequential 
studies. They are patients treated with high doses of nondepolarizing neuromuscular blocking agents 
such as vecuronium and pancuronium may have persistent weakness and fail weaning from the venti‑
lator, even after the blocking drugs have been discontinued [43,49]. Examination shows generalized 
weakness, normal or reduced reflexes, and normal sensation. Bilateral ptosis and facial and jaw muscle 
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weakness may be present [43]. Electrophysiologic features are reduced CMAP amplitude and decre‑
menting the response on 2‑3 Hz repetitive nerve stimulation (Figure 4). Patients with uncomplicated 
prolonged neuromuscular blockade recover completely, usually in 1‑2 weeks.
Proposed diagnostic algorithm
To optimize the likelihood of patient interaction for neuromuscular assessments, we advocate the im‑
plementation of sedation protocols. Daily interruption of sedative infusions confers the opportunity 
for serial neuromuscular examination and reduces the duration of mechanical ventilation [63]. Careful 
implementation of the structured MRC examination should be employed and documented serially as 
Figure 4. Repetitive nerve stimulation at a low stimulation rate (3‑5 Hz) in a patient with prolonged 
neuromuscular junction blockade. Decrement response suggests neuromuscular transmission defect
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a matter of routine. Patients exhibiting fixed or focal motor defects or persistent altered sensorium 
despite adequate sedation washout should undergo more advanced diagnostics (i.e., CNS imaging, 
electrophysiologic studies, and/or muscle biopsy) (Figure 5).
The decision to perform electrophysiologic testing and/or muscle biopsy in routine care has created 
an ongoing debate in the medical literature about its utility. Advocates for routine clinical examination 
who reserve neurophysiological testing and biopsy for unusual or severe instances of weakness cite 
the limitations, costs, and risks of this testing is an useful and efficient strategy. Establishing a highly 
specific or physiologically based diagnosis does not translate to a specific pharmacologic therapy. Fur‑
thermore, therapies currently employed to limit ICU‑AW should be applied to virtually all critically ill 
patients receiving mechanical ventilation.
Pathophysiological mechanisms
During the evolution of critical illness differents mechanisms of injury trigger and feedback to develop 
an adverse microenvironment for muscles and nerves. The muscular and nervous affectation does not 
escape the systemic involvement of different organs as a result of massive release of cytokines and other 
mediators that activate different cascade of mediators which produce electrical, metabolic, microvascu‑
lar and bioenergetic disturbances (Figure 6) [8,28].
Figure 5. Practical algorithm for diagnosis of critical illness polyneuromyopathy
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Inactivation of sodium ion channels
Rich and Pinter suggest that inactivation of sodium channels may contribute to critical illness rela‑
ted neuropathy, myopathy, or both [64]. During electrophysiological studies, severely affected muscle 
has been found to be electrically inexcitable to direct muscle stimulation [53]. In studies with animal 
Figure 6. Pathophysiological mechanisms of ICU‑AW
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models, this inexcitability has been proposed to be caused by changes (hyperpolarizing shift) in fast 
sodium channels leading to inexcitability of muscle fibers. In patients with septic shock, there are de‑
creased QRS amplitudes and increased QRS duration; while, in patients who recovered from septic 
shock, the electrocardiographic findings return to normal [65]. These observations are consistent with 
the notion of an acquired channelopathy because of the strong association between severe sepsis and 
ICU‑AW. This may result from post‑translation modification of sodium channels by glycosylation or 
phosphorylation or from increased expression of the embryonic sodium channel isoform that causes 
a shift toward more negative potentials [64]. The inactivation of sodium channels provoke decrease 
or absence of nervous excitability, whereas in the muscles produce inactivity and decline of muscular 
strength. Biopsy specimens have demonstrated normal appearance of muscles and nerves or the pre‑
sence of limited necrosis, suggesting that alterations in ICU‑AW are primarily functional [8,24].
Metabolic changes
Hyperglycemia, hyperosmolality, and hypoalbuminemia enhance muscular and nerve microvascular 
permeability, developing edema, reduce antioxidant capacity and affect the microcirculation due to 
thrombosis, edema and vasoconstriction [6]. Disturbances of the microcirculation to nerve and mu‑
scle may also explain the effects of neuromuscular blocking agents, corticosteroids, and antibiotics, 
particularly aminoglycosides with their known neural toxicity. However, there has been no statistical 
proof that antibiotics cause peripheral nerve dysfunction in sepsis [66]. Through increased capillary 
permeability induced by sepsis, neuromuscular blocking agents could have a direct toxic effect on 
peripheral nerve axons. These neuromuscular blocking agents may also cause functional denervation 
through their prolonged neuromuscular blocking action. A combination of functional denervation 
due to neuromuscular blocking agents and the subsequent direct effects of steroids together with pro‑
tracted immobility and a high‑stress catabolic state in muscle might be a possible mechanism. CIP and 
the additional effects of neuromuscular blocking agents could denervate muscle, and steroids could 
then induce the typical myopathic changes. Both the rapidly evolving myopathy reported by al‑Lozi 
and colleagues, which is characterized by destruction of thick filaments throughout the muscle fibers 
[67], and the acute necrotizing myopathy of intensive care may simply represent further stages of this 
process [68].
Microvascular changes
The pathophysiological mechanisms of ICU‑AW are multifactorial and commonly invoked pathways 
include ischemia or injury via mediators of inflammation [61]. How systemic inflammation would pro‑
duce nerve and muscle injury is unclear. In animal studies, inflammation of muscle tissue was found, 
represented by cellular infiltration and increased local levels of various inflammatory mediators. In 
human studies, high levels of various inflammatory mediators were found in muscle and nerve tissue 
of ICU‑AW patients [61]. The expression of adhesion molecules on vascular endothelium suggests the 
possible contribution of increased vascular permeability. Expression of E‑selectin, induced by sepsis is 
significantly elevated in the endoneurial and epineural vessels of patients with suspected CIP, suppor‑
ting the idea that microvascular changes may contribute to the axonopathy of CIP [69]. A dysfunctio‑
nal microcirculation leads to neuronal injury and axonal degeneration.This is believed to play a role 
in perpetuating local inflammation in peripheral nerves which suggests the endothelial‑cell activation 
as described in models of sepsis, with microvascular leak and alterations in the microvascular envi‑
ronment. Moreover, cytokines that are secreted in sepsis have histamine‑like properties that may also 
increase microvascular permeability [5]. Increased capillary permeability induces local tissue edema 
and activation of nitric oxide, causes arteriolar dilation, which may further slow capillary flow. Blood 
vessels supplying the peripheral nerves lack autoregulation, rendering these vessels susceptible to such 
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disturbances. Tissue injury leads to the influx of inflammatory cells and the release of inflammatory 
cytokines. While these local phenomena may be important, measurement of more global markers of 
inflammation, such as interleukin‑6 and tumor necrosis factor, has not shown them to be elevated in 
the serum of patients with CIP as compared to nonweak, critically ill control subjects [56]. Thus, essen‑
tial nutrients fail to reach the organ parenchyma.
Bioenergetic disturbances
Severe energy deficits will result, inducing a primary axonal degeneration, most likely distally if highly 
energy‑dependent systems involving axonal transport of structural proteins are involved. Bioenergetic 
failure is principally due to mitochondrial dysfunction with impaired capacity to generate ATP. Greater 
mitochondrial dysfunction has been observed in the skeletal muscle of patients who died from critical 
illness than in that of survivors of critical illness [44]. Hyperglycemia may also exacerbate this problem, 
perhaps by inducing neural mitochondrial dysfunction [61]. Failure of GLUT4 translocation from the 
perinuclear spaces to the sarcolemmal membrane was demonstrated to be a central mechanism of 
impaired glucose supply to muscle cells in CIM patients. There is a significant insulin resistance in 
critically ill patients as compared to healthy control subjects; insulin resistance is most severe in CIM 
patients. Electrical muscle stimulation corrected muscle‑specific adenosine monophosphate‑activated 
protein kinase failure, restored GLUT4 translocation in the sarcolemmal membrane, and prevented 
type‑2 fiber atrophy in CIM patients [70].
Cellular apoptosis
Changes in calcium (Ca++) homeostasis increases apoptosis and activation of proteolytic pathways. 
Different proteins degradative and apoptotic systems are found in muscle that have been implicated 
in CIM. Fiber atrophy is associated with myosin filament depolymerization that may be caused by in‑
creased expression of lysosomal enzymes and ubiquitin [71]. Patients who developed severe weakness 
after receiving high‑dose steroids showed increased ubiquitin expression [72]. This suggests that the 
ubiquitin‑ATP‑dependent proteolytic system may be initiated by corticosteroid use. Serum amyloid 
A1 transiently accumulates within the first few days in muscle of critical illness myopathy patients and 
is in vitro induced by interleukin 6 and tumor necrosis factor‑alpha [72]. Upregulation of part of the 
apoptotic system, specifically TGF‑beta/MAPK, has been found to be uniquely involved in CIM [74]. 
There is also evidence linking proteolytic and apoptotic systems as mechanisms of muscle fiber atrophy, 
necrosis, and cell death. Caspase‑3‑mediated apoptosis has been shown to cause extensive cell death in 
multiple organ systems during sepsis [75]. Furthermore, hormonal changes include relative deficiency 
of glutamine, decrease of anabolic hormones and increase of catabolic hormones [76].
Protein degradation
Other mechanisms that contribute to muscle wasting during critical illness are derived from protein de‑
gradation exacerbated by profound hypercatabolism and prolonged immobility, particularly those with 
sepsis [30]. Muscle atrophy begins just after few hours of bed rest associated with deep sedation, a situa‑
tion that applies to all muscle groups of the body, including the diaphragm. In the diaphragm, mechanical 
ventilation is associated with increased activity of the ubiquitin proteasome system, decreased levels of 
myosin heavy chain, and increased atrophic protein kinase B‑forkhead box subgroup O (AKT‑FOXO) 
signaling [29]. Muscle inactivity is a potent stimulus for protease activation leading to muscle protein 
breakdown and activation of the ubiquitin pathway of proteolysis. Immobility of the extremities, which is 
common in patients in the ICU, is related to the underlying illness in conjunction with prescribed bed rest 
and sedative‑related immobility. Together with ubiquitin‑proteasome system multiple proteolytic systems 
are also involved in muscle fiber atrophy, cathepsin B, lysosomal enzymes, and heat shock protein 72 [71].
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Differential diagnoses
Differential diagnoses of ICU‑AW commonly include GBS, metabolic neuropathies, toxic neuro‑
pathies, and neuropathies due to nutritional deficiencies. GBS, usually presents as symmetric, progres‑
sive, and ascending paralysis, sensory abnormalities, and areflexia, and 30% of patients require mecha‑
nical ventilation [77]. The nerve conduction velocity test shows decreased velocity in typical GBS, 
whereas normal conduction velocity and decreased action potential, both features of axonal neuro‑
pathy, can be seen in CIP and in axonal variants of GBS [77]. The major clinical difference between CIP 
and axonal variants of GBS is that GBS may follow an antecedent infective illness, surgery, or trauma 
for which the patient may have been initially admitted to the ICU [77]. Differentiation between BS and 
CIP is essential for the determination of therapeutic strategies, as intravenous immunoglobulin or 
plasma exchange is required in GBS [77], while supportive care is needed in critical illness polyneuro‑
pathy. Onset of clinical signs and electrophysiological changes in peripheral nerves and muscles during 
the development of CIP and myopathy can be rapid [18,28,38,78,79]. Albumin‑cytologic dissociation 
in cerebrospinal fluid can help differentiate between the two diseases. The cerebrospinal fluid protein 
concentrations in patients with GBS are usually normal at the beginning of the disease, and increase in 
over 90% of patients by the end of the second week [77], whereas protein concentrations are usually 
unchanged in CIP and CIM. Furthermore, a nerve biopsy and detection of anti‑ganglioside antibodies 
could be helpful in differentiating critical illness polyneuropathy from axonal GBS [77]. The criteria for 
differentiation are specified in Table IV.
Ionic abnormalities such as hypokalemia, hypophosphatemia, and hypermagnesemia, in addition to 
the use of several drugs including neuromuscular blocking agents, cancer chemotherapy, statins, and 
Investigation CIP CIM CINM
Physical
examination
 • Distal muscle weakness
 • Distal sensory deficit
 • Normal or depressed deep 
tendon reflexes
 • Proximal muscle weakness
 • Normal sensory testing
 • Normal or depressed deep 
tendon reflexes
 • Proximal and distal muscle 
weakness
 • Distal sensory deficit
 • Depressed deep tendon 
reflexes
Electrophysiology 
studies
 • Decreased CMAP and 
decreased SNAP
 • Normal MUAP
 • Normal or near‑normal
 • conduction velocity
 • Decreased CMAP and normal 
SNAP
 • Decreased MUAP
 • EMG shows short duration, 
low‑amplitude activity
 • Decreased CMAP and SNAP
 • Decreased MUAP
 • EMG shows short duration, 
low‑amplitude activity
Histology  • Axonal degeneration of distal
 • motor and sensory nerves
 • Thick filament (myosin) loss, 
type II fiber (fast twitch) 
atrophy, necrosis
 • Axonal degeneration and 
evidence of loss in myosin, 
type II fiber atrophy, and 
necrosis
Pathophysiological 
processes
 • Nerve ischemia
 • Nerve microvascular injury 
Nerve mitochondrial injury
 • Sodium channelopathy
 • Mitochondrial dysfunction
 • Oxidative stress
 • Sodium channelopathy
 • Ubiquitin–proteasome 
proteolysis
 • Mixed
Table IV. Pathophysiological features of Intensive Care Unit‑Acquired Weakness (ICU‑AW).
CIM = critical illness myopathy; CINM = critical illness neuromyopathy; CIP = critical illness polyneuropathy; 
CMAP = compound muscle action potential; EMG = electromyography; MUAP = muscle unit action potential; 
SNAP= sensory nerve action potential.
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antiretrovirals, should be differentiated because each can affect neuromuscular transmission and cau‑
se muscle weakness [80‑82]. Propofol infusion syndrome, a syndrome involving severe metabolic 
acidosis, cardiac failure, rhabdomyolysis, renal failure, and hypertriglyceridemia after high‑dose pro‑
pofol (5 mg/kg/h) administration for long periods (> 48 hours), is also seen in intensive care units and 
should be taken into consideration [83]. Mild, chronic polyneuropathies such as diabetic polyneu‑
ropathy may affect predominantly the nerves of respiration. After admission to the critical care unit, 
sepsis may worsen a preexisting polyneuropathy. Occasionally, defects in neuromuscular transmis‑
sion, myasthenia gravis, and Lambert‑Eaton myasthenic syndrome present with primary respiratory 
failure. Diagnostic considerations in this group include anoxic myelopathy, affecting mainly anterior 
horn cells, which may result from cardiac arrest, atherosclerosis, surgery of the aorta or severe pul‑
monary disease [84].
CK levels vary in CIM but are usually normal or mildly elevated, except in acute necrotizing myo‑
pathy where CK levels are high. The signature pathological finding is a distinctive loss of thick myo‑
sin filaments. However, there can be various degrees of type 1 or type 2 muscle fiber atrophy as well 
as necrosis [71]. In an observational study of the first week of critical illness myopathy, Bierbrauer 
and colleagues described histological evidence in the vastus lateralis muscle of selective type 2 fiber 
atrophy coupled with depletion of myosin heavy chain IIa isoform messenger RNA in patients with 
inexcitable peroneal muscle membrane as defined by distal CMAP amplitudes below 3.0 mV [60]. 
There has been debate regarding the need for a muscle biopsy in patients with possible CIM [51,59]. 
The controversy surrounds whether the biopsy results alter treatment decisions. Although Lacomis 
and colleagues have listed histopathological findings of myosin loss as one of their diagnostic criteria, 
they do not advocate muscle biopsy in cases without apparent diagnostic uncertainty. Muscle ultra‑
sound data from healthy controls were compared to that derived from septic patients in the first 2 
weeks; most septic cases have elevated mean muscle echotexture and fasciculations in more arm and 
leg muscle groups [54,55].
There have been conflicting reports about the effect of critical illness neuromuscular complications 
on the intensive care unit mortality rate. A systematic literature review found no increase in adju‑
sted mortality of intensive care unit patients with neuromuscular complications but demonstrated 
prolongation of mechanical ventilation and intensive care unit and hospital stay [10]. However, in a 
prospective cohort of severe sepsis cases who underwent weekly neurologic examinations and nerve 
conduction studies within 72 hours of developing severe sepsis, an abnormal baseline nerve conduc‑
tion study was predictive of increased hospital mortality (55%), whereas none of the patients with nor‑
mal baseline nerve conduction studies died [85]. Most of the affected patients had electrophysiological 
evidence of both critical illness myopathy and critical illness neuropathy.
Treatment and management
In the absence of specific therapy, the management involves the close collaboration of neurologists, 
neurophysiologists, and intensivists. The therapeutic strategies should be directed to the control of 
sepsis, SIRS and organ dysfunction and includes antibiotics to counteract infection, surgical drainage 
of an infected focus, and the use of inotropic drugs and fluid replacement to control hypotension. Se‑
veral attempts at controlling early stage of the SIRS have shown variable results. These attempts inclu‑
de monoclonal and polyclonal antibodies directed against bacterial endotoxin, monoclonal antibodies 
to tumor necrosis factor‑alpha, fusion protein constructs of soluble tumor necrosis factor receptors, 
IL‑1 receptor antagonists [86], the platelet activating factor receptor antagonist, BN5202 [87], and 
the N‑acetylcysteine [88]. There also was no beneficial effect of reducing disease severity using high 
intravenous immunoglobulins [89], and IgM‑enriched intravenous immunoglobulin [90]. Avoiding 
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or minimizing some pharmacological agents, such as corticosteroids and neuromuscular blocking 
agents represent the best strategy way for early recovering of muscle and nerve [3,4,8,25]. Both agents 
should be avoided or utilized at minor therapeutic dose and for shorter periods of time [3,4,8,25]. 
However, although the mean daily dose of corticosteroids may predict physical outcome at 1 year [91], 
a recent Cochrane review concluded there is no effect of corticosteroids on CIP, except for fewer new 
shock episodes [92]. Shortening the time in deep sedation is another useful strategy for preventing 
ICU‑AW. Physical function at 1 and 2 years is negatively impacted by longer duration of ICU stay [93]. 
This strategy involves minimizing the sedation with the goal of getting patients up and out of bed. The 
discontinuation of deep sedation is a critical first step in optimizing patient activity and awareness. 
Deep sedation is associated with undesirable effects that can be avoided. It increases the possibility of 
hemodynamic instability, the incidence of delirium and prolongs the duration of mechanical ventila‑
tion with the associated risk of pneumonia ans sytemic infection that implies [7,8,21,94]. Moreover, 
profound sedation prolongs the time of immobilization and prevents adequate and effective rehabili‑
tation favoring muscle atrophy [7,8,21,94]. Finally, over‑sedation has economic consequences due to 
extension of stay in ICU and in the hospital. It is advisable as far as possible to implement protocols 
of daily interruption of sedation, in order to withdrawal as quickly as possible [94]. De Jonghe et al. 
noted that use of a sedation algorithm designed to allow patients to be more alert was associated with a 
50% reduction in pressure sores, presumably because of reductions in sedative‑related immobilization 
[95]. Furthermore, the interruption of daily sedative use during mechanical ventilation increases the 
percentage of days during which patients are awake and able to follow commands [63]. The changes 
in ICU care to reduce sedative use improve in‑hospital activity levels in a group of patients in the 
medical ICU [96].
Currently, therapeutic interventions to prevent or attenuate ICU‑acquired weakness and functional 
impairment after critical illness are limited to proper nutrition, moderate glucose control, early mobili‑
zation and rehabilitation [7,8,34,21]. To date, the role of nutritional and supplemental therapies include 
protein and amino acid supplementation, antioxidant therapy, and hormonal therapy [78]. However, 
studies examining nutritional supplementation are difficult to extrapolate to the treatment of ICU‑AW, 
in that they typically focus on enhancement of the immune system or other global outcomes and not 
the correction of myopathy or neuropathy. Intake of specific substrates, such as glutamine and glu‑
tathione, might have a beneficial effect on recovering neuromuscular impairments in the critically ill 
patient. However, there are still no data to justify its use if the only purpose is to recover neuromuscular 
function, while aggressive renutrition schedules should be avoided in order to prevent re‑nutrition 
syndrome and further deterioration of muscle function [78].
Insulin antagonizes the different routes of damage generated during hyperglycemia, and also has 
neuroprotective effects, so it is the agent of choice for blood glucose control strategies. Insulin exerts 
anti‑inflammatory effects, endothelial protection, improvement of dyslipidemia, and neuroprotective 
effects in animals and is also an anabolic hormone [97]. Although intensive glucose control was earlier 
thought to be helpful in reducing the incidence and severity of critical illness polyneuropathy [31], the 
NICE‑SUGAR Study argues against tight glucose control given the higher mortality risk associated 
with increased moderate to severe hypoglycemia [98]. Intensive insulin therapy should be avoided due 
to the risk of hypoglycemia [97,99,100]. The American Diabetes Association currently recommends 
target blood glucose of 144 to 180 mg per deciliter to reduce the risk of hypoglycemia in critically 
ill patients [101]. Therefore, according to a 2014 Cochrane update, intensive insulin therapy reduces 
ICU‑AW (risk ratio 0.65), and it reduces the duration of mechanical ventilation, intensive care unit 
stay, and 180‑day mortality. Because hypoglycemia is a risk, Cochrane reviewers recommend that con‑
sequences and prevention of hypoglycemia need further study [92].
The implementation of an early mobility and intensive rehabilitation program improves outcomes 
in ICU‑AW patients [3,4,8,25]. When compared with a case series of patients with ICUAW who 
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did not receive structured physical therapy, evidence suggested those who receive physical reha‑
bilitation were more frequently discharged home rather than to a rehabilitative facility, although 
confidence intervals included no difference [57]. Passive mobilization prevents muscle atrophy, pro‑
found venous thrombosis and decubitus ulcers. Physical and occupational therapies increase the 
possibility to achieve good functional outcomes. Daily exercises especially targeted to the diaphragm 
and respiratory muscles help greatly in the process of weaning from mechanical ventilation. Other 
interventions show promise, but fewer data proving patient benefit exists. Furthermore, execution 
of a rehabilitation program requires a collaborative effort among members of the multi‑disciplinary 
team to coordinate, care for, and provide safe mobilization of patients in intensive care units. Finally, 
electrical muscle stimulation (EMS) may be an alternative therapy for patients who cannot actively 
exercise or others disabling comorbidities and in patients unable to cooperate [102]. This technique 
may maintain muscle strength and joint range of motion, improve outcomes of ventilation, and re‑
duce activity limitations [103].
Prognosis
ICU‑AW is associated with increased mortality rate and rehabilitation problems [104]. Rehabilitation 
therapy is likely to be beneficial in speeding the recovery of these patients [105]. Prognosis for recovery 
from CIM is more favorable than that of CIP alone [17], unless muscle necrosis is severe, or CINM 
[106]. Children fair better than adults for a favorable recovery was thought to be as low as 50% [107]. 
However, if the polyneuropathy is severe, recovery may take months. In especially severe cases, re‑
covery may not occur [6]. Neurophysiological studies performed at intervals can aid in determining 
prognosis of recovery [108].
Conclusions
ICU‑AW is a frequent complication of critical illness. Recovery is often slow and incomplete in such 
patients, particularly those who are elderly. There are three principal clinical forms; CIP CIM, and the 
mixed form CINM. They are characterized by generalized muscle weakness including respiratory com‑
promise that makes difficult to wean from mechanical ventilation. Electrophysiological studies can 
help in differential diagnosis. Occasionally, muscle biopsy is necessary. Aggressive treatment of risk 
factors is essential. Early diagnosis is important to apply all prevention measures that are needed. A 
multidisciplinary approach is essential and, due to the lacking of specific therapy, proper management 
is based on minimizing or avoiding triggers, controlling sepsis and inflammatory states, minimizing 
the use of sedation, strict glycemic control and early and aggressive plan of mobilization and rehabili‑
tation to reduce muscle reconditioning and dysfunction.
Question for further research
There is some evidence that some patients with CIM demonstrate increased CMAP duration, but 
this finding needed further validation.
The review in brief
Clinical question Because the diagnosis and the management of ICU‑AW can be sometimes difficult, this narrative review 
aims to help in organizing a practical approach to the diagnosis and management of ICU‑AW patients.
Type of review Narrative
Conclusions Electrophysiological studies can help in differential diagnosis, occasionally, muscle biopsy is necessary. 
Aggressive treatment of risk factors is essential. Early diagnosis is important to apply all prevention 
measures that are needed. A multidisciplinary approach is essential, proper management is based on 
minimizing or avoiding triggers, controlling sepsis and inflammatory states, minimizing the use of 
sedation, strict glycemic control and early and aggressive plan of mobilization and rehabilitation to 
reduce muscle reconditioning and dysfunction.
Limitation Lack of specific therapy.
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